Masimo Co. (NASDAQ:MASI) Receives $143.57 Consensus PT from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $143.57.

A number of equities analysts have recently weighed in on MASI shares. Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $117.00 to $160.00 in a research note on Monday, March 25th. Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and increased their price objective for the stock from $148.00 to $170.00 in a report on Monday, April 15th. Piper Sandler raised shares of Masimo from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $126.00 to $160.00 in a research report on Monday, June 3rd. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Tuesday. Finally, StockNews.com raised shares of Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th.

Masimo Price Performance

NASDAQ MASI opened at $111.96 on Wednesday. Masimo has a 1 year low of $75.22 and a 1 year high of $153.93. The business’s fifty day moving average is $124.44 and its two-hundred day moving average is $128.79. The stock has a market capitalization of $5.95 billion, a P/E ratio of 76.16 and a beta of 0.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.31 and a current ratio of 2.31.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, May 7th. The medical equipment provider reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. The business had revenue of $492.80 million during the quarter, compared to the consensus estimate of $487.70 million. Masimo had a return on equity of 13.26% and a net margin of 4.01%. Masimo’s revenue was down 12.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.87 earnings per share. On average, research analysts forecast that Masimo will post 3.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Masimo

In related news, Director Craig B. Reynolds sold 40,000 shares of Masimo stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the completion of the transaction, the director now directly owns 7,406 shares of the company’s stock, valued at approximately $1,008,475.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Masimo

A number of institutional investors and hedge funds have recently bought and sold shares of MASI. Cardinal Capital Management lifted its position in shares of Masimo by 4.6% during the second quarter. Cardinal Capital Management now owns 15,440 shares of the medical equipment provider’s stock worth $1,945,000 after purchasing an additional 676 shares in the last quarter. Juncture Wealth Strategies LLC raised its position in shares of Masimo by 294.3% during the second quarter. Juncture Wealth Strategies LLC now owns 7,992 shares of the medical equipment provider’s stock worth $1,007,000 after acquiring an additional 5,965 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 111 shares during the period. Farallon Capital Management LLC boosted its holdings in Masimo by 13.6% in the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock valued at $218,742,000 after acquiring an additional 177,914 shares during the last quarter. Finally, Tidal Investments LLC increased its position in Masimo by 14.1% in the first quarter. Tidal Investments LLC now owns 2,179 shares of the medical equipment provider’s stock worth $320,000 after purchasing an additional 269 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.